Search

everythinglearnresearchcommunity

for

Search:↓

American men seeking infertility evaluation are generally older, more obese, have longer infertility duration, and different lifestyle habits compared to Canadian men.

American men are older, more obese, and have longer infertility than Canadian men.

Finasteride and testosterone are the drugs most linked to male infertility, but many other potential drugs may be under-reported.

Reproductive gynecologists are the main referrers for male infertility evaluations in North America.

Older men have different fertility histories and factors affecting fertility, suggesting they may benefit from earlier fertility evaluations.

Testosterone replacement therapy can prevent men from fathering children and should not be used by those wanting to stay fertile.

Cell transplantation faces challenges in genitourinary reconstruction, but alternative tissue sources and microencapsulation show promise.

The 2024 guideline updates recommendations for genetic testing, imaging, and sperm retrieval in male infertility.

The document explains how certain drugs block hormones to treat cancers like breast and prostate cancer.

Healthcare providers should start with simple fertility tests and treatments before referring patients to specialists.

Some common medications can harm male fertility, but many effects can be reversed.

New treatments for male hypogonadism are effective and should be personalized.

Hormonal treatment in transgender women reduces semen quality, but stopping treatment may improve it.

With careful management, people with congenital adrenal hyperplasia can have successful pregnancies and become parents.

Androgen receptors in the mouse brain may explain cognitive and mood changes in prostate cancer treatment.

Removing an adrenal tumor can significantly reduce high androgen levels in postmenopausal women.

The guidelines recommend informed consent for gender-affirming treatments and stress the importance of personalized, culturally sensitive care for transgender individuals.

Erectile dysfunction is increasingly common in men under 40, with many physical and psychological causes, and various treatment options available.

Early diagnosis and individualized treatment improve outcomes for Congenital Adrenal Hyperplasia.

Men, especially older ones with health issues like prostate cancer, may have worse COVID-19 outcomes and could benefit from therapies targeting male hormones.

Finasteride treats enlarged prostate, shrinks it, improves urination, but may cause sexual dysfunction and isn't for women or children.

The length of the CAG repeat in the androgen receptor gene affects the risk and progression of prostate cancer, BPH, infertility, and undermasculinized genitalia.

Testosterone therapy and surgeries like mastectomy improve transgender men's lives and mental health with low risks and high satisfaction.

Finasteride treats enlarged prostate and baldness, but may cause limited urinary improvement and sex-related side effects.

The review highlights the need for more research on transgender dermatology, the role of dermatologists in gender affirmation, and the effects of hormone therapy on skin and hair.

The 2018 update to the ED care model added a new severity score and stressed a detailed evaluation of both physical and psychological aspects.

Negative expectations can cause adverse effects in dermatology treatments, like with finasteride for baldness, and careful communication can help reduce these nocebo responses.

Finasteride can cause sexual dysfunction and depression, which may persist and require hormonal treatment.

Testosterone therapy for transmasculine individuals is generally safe with medical supervision, improves mental health, and has mixed effects on physical health.

5-alpha reductase inhibitors may reduce bladder cancer recurrence and improve survival.